ROIV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ROIV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Roivant Sciences's enterprise value is $2,619.5 Mil. Roivant Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $123.2 Mil. Therefore, Roivant Sciences's EV-to-Revenue for today is 21.26.
The historical rank and industry rank for Roivant Sciences's EV-to-Revenue or its related term are showing as below:
During the past 3 years, the highest EV-to-Revenue of Roivant Sciences was 149.89. The lowest was 18.50. And the median was 62.41.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-04-26), Roivant Sciences's stock price is $10.88. Roivant Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.16. Therefore, Roivant Sciences's PS Ratio for today is 69.30.
The historical data trend for Roivant Sciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences Annual Data | |||||||
Trend | Mar21 | Mar22 | Mar23 | ||||
EV-to-Revenue | - | 37.28 | 79.38 |
Roivant Sciences Quarterly Data | |||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 121.29 | 79.38 | 91.81 | 85.50 | 27.34 |
For the Biotechnology subindustry, Roivant Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Roivant Sciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Roivant Sciences's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 2619.490 | / | 123.241 | |
= | 21.26 |
Roivant Sciences's current Enterprise Value is $2,619.5 Mil.
Roivant Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $123.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (NAS:ROIV) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Roivant Sciences's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 10.88 | / | 0.157 | |
= | 69.30 |
Roivant Sciences's share price for today is $10.88.
Roivant Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Roivant Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Venker | officer: President & COO | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Keith S Manchester | director | C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L |
Daniel Allen Gold | director | 6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119 |
Qvt Financial Lp | 10 percent owner, other: Director by Deputization | 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106 |
Svf Investments (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET, LONDON X0 W1K3JP |
Rakhi Kumar | officer: Chief Accounting Officer | C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Performance Llc | 10 percent owner | 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020 |
Viking Global Opportunities Parent Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Softbank Vision Fund L.p. | 10 percent owner | AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH |
Meghan Fitzgerald | director | C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511 |
Richard Pulik | officer: CFO | SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB |
Vivek Ramaswamy | director | C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902 |
Dexcel Pharma Technologies Ltd. | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 3060000 |
From GuruFocus
By Marketwired • 08-14-2023
By GlobeNewswire GlobeNewswire • 02-22-2023
By GuruFocus Research • 10-05-2023
By Marketwired • 09-26-2023
By Marketwired • 07-11-2023
By Marketwired • 10-23-2023
By Marketwired • 06-28-2023
By GuruFocus Research • 10-03-2023
By Marketwired • 10-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.